PMID- 31256190
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20200225
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 25
DP  - 2019 Jun 30
TI  - The Association Between the Use of Antiarrhythmic Drugs in Non-Valvular Atrial 
      Fibrillation and Patient Prognosis Using Data from the China Atrial Fibrillation 
      (China-AF) Registry.
PG  - 4856-4868
LID - 10.12659/MSM.916855 [doi]
AB  - BACKGROUND Results of the landmark Atrial Fibrillation Follow-Up Investigation of 
      Rhythm Management (AFFIRM) trial comparing rhythm control and rate control 
      strategies has led to dramatic changes in the pharmacological management of 
      non-valvular atrial fibrillation (NVAF) patients. We sought to investigate the 
      effect of antiarrhythmic drugs (AADs) on the clinical outcomes of NVAF patients 
      using "real-world" data from China. MATERIAL AND METHODS We evaluated the 
      association between AAD usage and clinical outcomes using clinical data of 8161 
      NVAF patients who were AAD-naive before enrollment in the China Atrial 
      Fibrillation Registry, recruited between August 2011 and February 2017. The 
      primary outcome was all-cause mortality. RESULTS Compared with 6167 patients who 
      never used any AADs, 1994 patients in the AAD group had lower incidence (per 100 
      person-years) of all-cause mortality (1.44 versus 3.91), cardiovascular death 
      (0.45 versus 2.31), ischemic stroke (1.36 versus 2.03), and cardiovascular 
      hospitalization (9.83 versus 10.22) over a mean follow-up duration of 316.7+/-90.4 
      days. After adjusting for potential confounders, AAD usage was associated with a 
      lower risk of all-cause mortality [hazard ratio (HR): 0.50, 95% confidence 
      interval (CI): 0.31-0.81] and decreased risk of cardiovascular death (HR: 0.30, 
      95% CI: 0.13-0.68). Subgroup analysis revealed AAD was associated with higher 
      risk of cardiovascular hospitalization among female patients. CONCLUSIONS AAD 
      usage was associated with lower risk of 1-year all-cause mortality and 
      cardiovascular death in "real-world" patients with NVAF.
FAU - Hou, Xiao-Xia
AU  - Hou XX
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      National Clinical Research Center for Cardiovascular Diseases, Beijing, China 
      (mainland).
AD  - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, 
      Beijing, China (mainland).
FAU - Du, Xin
AU  - Du X
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      National Clinical Research Center for Cardiovascular Diseases, Beijing, China 
      (mainland).
FAU - Zheng, Danni
AU  - Zheng D
AD  - Centre for Big Data Research in Health, University of New South Wales, Sydney, 
      New South Wales, Australia.
AD  - The George Institute for Global Health, University of New South Wales, Sydney, 
      New South Wales, Australia.
FAU - Li, Yan-Ming
AU  - Li YM
AD  - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, 
      Beijing, China (mainland).
FAU - He, Liu
AU  - He L
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      National Clinical Research Center for Cardiovascular Diseases, Beijing, China 
      (mainland).
FAU - Li, Xin-Xu
AU  - Li XX
AD  - Center for Drug Evaluation, China Food and Drug Administration, Beijing, China 
      (mainland).
FAU - Dong, Jian-Zeng
AU  - Dong JZ
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      National Clinical Research Center for Cardiovascular Diseases, Beijing, China 
      (mainland).
AD  - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20190630
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Anti-Arrhythmia Agents)
SB  - IM
MH  - Aged
MH  - Anti-Arrhythmia Agents/pharmacology/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/*mortality
MH  - China
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Registries
MH  - Risk Factors
MH  - Stroke/complications
MH  - Treatment Outcome
PMC - PMC6621684
EDAT- 2019/07/01 06:00
MHDA- 2020/01/31 06:00
PMCR- 2019/06/30
CRDT- 2019/07/01 06:00
PHST- 2019/07/01 06:00 [entrez]
PHST- 2019/07/01 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
PHST- 2019/06/30 00:00 [pmc-release]
AID - 916855 [pii]
AID - 10.12659/MSM.916855 [doi]
PST - epublish
SO  - Med Sci Monit. 2019 Jun 30;25:4856-4868. doi: 10.12659/MSM.916855.